

YOUR PARTNER IN DISCOVERY 您研发的伙伴

An international, chemistry-based CRO, on a mission to accelerate the discovery and development of high-quality drugs.


专注化学的国际CRO,加速高质量药物的研发



I CC is on a mission

to accelerate the





Initial Discovery

Liverpool Univ.

Enantioselective reduction of pyridines

Technologies Development

- · Cross coupling
- · Asym. hydrogenation
- Cyclisation chemistry

New Technologies

- Photochemistry
- · Biocatalysis

discovery and development of ~ 50 people • > 1,000 products now high-quality drugs available from stock though improved • > 100 customers access to the 3D supplied chemical space. • New £2.25m funding

2020

agreement

 Strengthened management team Established SAB 速高质量药物的 ISO-9001 certification 开发与发展。

凯诺科的使命: 通过先进的三维 化学空间方法加




LCC's Products

- DEL
- FBLD
- PROTACs
- APIs
- VL





LCC designs, produces and supplies **high quality chiral chemicals** with **proprietary technologies**. LCC develops new and **innovative solutions** to access novel & rationally designed chiral components.



Our Mission

Accelerate your discovery

- 3D Chemical space enhancement
- Intelligent design of BBs for specific applications
 (DEL, FBLD, PROTACs, ...)
- Personalised support

 (tailored collections, SAR studies, nearest neighbour analogues, scale-up, ...)

凯诺科利用专有技术,设计并生产高质量手性化合物,提供新颖的解决方案,快速找到创新的、合理的手性成分。




LCC's compounds are **specifically designed** to be used in various screening techniques / programme type.


凯诺科专业设计的产品,可以在不同的筛选技术和项目类型中使用。

DEL Scaffolds (mono/di/tri) NH₂ "CO₂H


DNA-compatible Synthetic Handle




Ro3, 19-F, Covalent, Enantioprobe



Semi-Flexible (low Rot B.)



>99% ee mg to multi-kg



5,000,000 Lead-like Molecules



DEL (DNA-Encoded Library): Collection of molecules attached to DNA carrying unique information about the identity of the library member.

BBs Requirements:

- Synthetic handles specific to reactions on-DNA
- More than one synthetic handle is required to enhance the diversity of the library (1)

Commercially available scaffold types according to the number of synthetic handles: (2)



Mono: 73% (130K)


Di: 25%(45K)

Tri: 2% (4K)

Lack of availability for di- and trifunctionalised scaffolds

LCC's collection of DEL synthesis contains 11K compounds, that are pre-categorised according to the number and nature of the handle(s) to facilitate the selection process.

Synthetic Handles




(1) Madsen, D. et al. (2020) "Chapter Four - An overview of DNA-encoded libraries: A versatile tool for drug discovery" in Witty, D. R. & Cox, B. (ed.) *Progress in Medicinal* Chemistry, Volume 59. Elsevier, 181-249. (2) Martín, A.; Nicolaou, C. A.; Toledo, M.A. Commun *Chem*, 2020, 3,1. Lilly's commercially available scaffolds were defined as BBs readily available from Enamine and Sigma.



LCC's DEL synthesis are designed to be successfully used in DNA-compatible reactions, and have a diverse set of options for the synthetic handles, covering some of the gaps in existing chemical space.

凯诺科DEL合成产品可成功适应DNA反应,提供多种反应点选择,填补了目前化学相关构型的空白。




Key Criteria:


- Diverse array of heterocyclic compounds
- Extended selection of 3D-rich synthons
- Synthetic handles compatible for reactions on-DNA
- Mono / Di / Tri functionalised compounds
- Low Molecular Weight
- Racemic and chirally-pure material available

Ready to use scaffolds



LCC has increased availability of compact, cyclic-based, stereo-defined fragments. LCC can help to select the best fragments to **complement existing library**. 凯诺科提供最好的片段,更快地扩展现有化合物库。





Project specific substitution patterns and warheads are available on demand. 根据需求定制基团和取代构型



Coupling between LCC's sp3-rich secondary amines and the selected warheads (such as the acrylamide, chloroacetamide, and diazirine for example), offers an opportunity to diversify existing covalent fragment libraries.


凯诺科通过偶联可提供更多样化的片段库。

Selected examples



LCC provides semi-flexible linkers, resulting in better controls of final PROTACs shape and orientation; facilitating modelling step and increasing efficiency.

凯诺科提供半柔性Linkers,更好地控制构型和定位,提高成功率。




Key Criteria:


- Systematic changes in conformation
- · Selected exit vectors for ligand coupling
- Good variety of chain lengths
- No additional HBD's
- Reduce number of rotatable bonds
- Racemic and chirally-pure material available


可提供消旋的、纯手性分子




Representative examples of our **semi-flexible linkers sub-collection** for PROTACs:










Project specific exit vectors and substitution patterns are available on demand. 根据需求定制靶向配体和取代构型



Piperidines and pyrrolidines are ubiquitous scaffolds in small molecule drugs (>60% of the marketed small molecules drugs are bearing these moieties). The importance of LCC's compounds can be highlighted by their presence in several of the top 200 pharmaceutical products sold in 2018. 凯诺科产品出现在2018年最畅销二百药物产品中。





With extended production capabilities and facilities, LCC can accelerate your discovery by providing large scale and high-quality API & key intermediates. 凯诺科拥有一流设备,可提供中试所需的高质量API和中间体。













Enantioenriched material with high ee (up to 99.5% on demand) 凯诺科所有产品都提供ee值并确认绝对构型



Aim: Design and virtually synthesise a lead-like library via decoration of LCC's proprietary 3D-scaffold collection.



Workflow

- 1. Identification of (nucleophilic) synthetic handles on diverse set of 3D fragments
- 2. Selection of 5 robust chemical transformations
- 3. Selection of diverse set of commercially-available (electrophilic) reagents using PickR™
- 4. Virtual synthesis of 2D library via scaffold enumeration
- 5. Conformational sampling and generation of 3D library
- 6. ~Ro4 and drug-likeness property filters
- 7. Analysis of finished library


3 Key Design Parameters:


- Quality
 - ~Ro4 lead-like chemical space >90% synthesis success rate
- Diversity
 Wide spread of sp²-sp³ character & MW
 Diversity-controlled reagent selection
- Novelty
 Proprietary scaffold collection
 SureChemBL novelty assessment


Accelerate Hit-ID / Hit-to-Lead 加速先导化合物的定位



Selected examples of **robust chemical transformations** between LCC's 3D fragments commercially-available reagents:









LCC is utilizing its proprietary knowledge to design set of chemical tailored to bespoke projects .


凯诺科利用专有技术根据客户需求设计并定制手性化合物。

Speciality	
Request	
Proposal	
Order	
Success rate	

凯话科和	īIJ
Scaffolds for DEL	
Synthetic handles specific to the project	
386 compounds, including ~350 newly designed BBs	
79 scaffolds	
96 %	

Linkers for PROTACs
Identical core with various exit vectors
36 compounds, including 15 newly designed BBs
36 linkers
100 %

SAR studies and hit-to-lead optimisation
Nearest neighbour analogues
28 compounds designed for the project
11 building blocks
100 %






DEL: Hits to Lead Candidate(s)

	Supply of LCC's 3D-rich scaffolds
Step 1	for DNA-encoded library elaboration
	Rapid access to off-DNA hit(s)
Step 2	(includingevery enantiomers)
Step 3	Provision of nearest neighbour analogues
Step 4	Supply of functionalised scaffolds for rapid hit(s) expansion

(1) All new compounds are fully characterised, including the determination of the nature of the stereocenter (s).





Open-Access

Access LCC's specialised compounds through:

- LCC website & Custom sd-files
- E-commerce (eMolecules, Chemspace,…)
- Distributors (Sigma, Apollo, Namiki,…)

Private (CDA protected)

Access LCC's private compounds through:

- Custom sd-files
- Computational partners (Cresset, BioSolvelT,···)
 - for the lead-like space

(1) Oct. 2020



Accelerate your discovery

and bring new compounds to market, faster, better and easier.











LCC is offering access to novel, **chirally-pure compounds** to develop high-quality drugs, through existing catalogue, ongoing pipeline, virtual library, and much more.

凯诺科利用现有化合物库,个性化设计、虚拟库等技术,提供新颖的、纯手性化合物,助力高质量药物研发。

Intelligent design of BBs for specific applications (DEL, FBLD, PROTACs, ...) >11K 3D-rich stereodefined (N-) heterocyles tailored collection, SAR, nearest neighbour analogues, ...)

Accelerate your discovery

and bring new compounds to market, faster, better and easier.

Head Quarter: Liverpool ChiroChem Ltd.

Address: Crown Street, Liverpool, L69 7ZD, UK

Contact: Dr. Marie Hoffmann

Telephone: +44(0)1517942936

Email: marie.hoffmann@liverpoolchirochem.com

凯诺科(泰州)药物研发有限公司

地址: 江苏省泰州市医药高新区长江大道18号

滨江原料药公共服务平台

邮箱: sales@liverpoolchirochem.com

电话: +86(0)52386810091

网址: www.liverpoolchirochem.com

更快、更好、更专业,为您的研发加速!

